View
4
Download
0
Category
Preview:
Citation preview
Ultima ratioLast-line-Therapie bei Multiresistenz
O. Janata
Inhalt
• Chronologie der last-line-therapy
• Aktuelle in vitro Daten
• Perspektive
• disclosure - supported by SHIONOGI
Zufall
Produktion von Antibiotika Resistenz gegen Antibiotika
Lechuguilla Cave, Carlsbad Caverns National Park, New Mexico.
Bhullar K, Waglechner N, Pawlowski A, Koteva K, Banks ED, et al. (2012) Antibiotic Resistance Is Prevalent in an Isolated Cave Microbiome. PLOS ONE 7(4): e34953. https://doi.org/10.1371/journal.pone.0034953
Urban brown rats (Rattus norvegicus) as possible source of multidrug-resistant Enterobacteriaceae and meticillin-resistant Staphylococcus spp., Vienna, Austria, 2016 and 2017Amélie Desvars-Larrive 2019
Ultima ratio – Last-line-Therapie
Historie der last line
Zeitraum Problem Antibiotika
1980 – 2000 Betalaktamasen Amoxicillin Clav, Ampicillin SulbCeftaxim, Ceftriaxon, Ceftazidim
2000 – 2015 ESBL Piperacillin Tazobactam, CefepimImipenem Cilastatin, Meropenem
ab 2015 MRGN Ceftolozan Tazobactm, Ceftazidim AvibactamImipenem Cilastatin Relebactam, Meropenem Vaborbactam
ab 2020 Metallo – Betalaktamasen CefiderocolEravacyclin, Plazomicin
? ? …
Vancomycin
Mississippi Mud
Trends in the estimated number of MRSA and G3CREC bacteremias in the European region.
de Kraker MEA, Davey PG, Grundmann H, on behalf of the BURDEN study group (2011)Mortality and Hospital Stay Associated with Resistant Staphylococcus aureus and Escherichia coli Bacteremia: Estimating the Burden of Antibiotic Resistance in EuropePLoS Med
third-generation cephalosporin-resistant Escherichia coli (G3CREC)
HWI & Intraabdominelle Infekte
Historie der last line
Zeitraum Problem Reserve – Antibiotika
1980 – 2000 Betalaktamasen Amoxicillin Clav, Ampicillin SulbCeftaxim, Ceftriaxon, Ceftazidim
2000 – 2015 ESBL Piperacillin Tazobactam, CefepimImipenem Cilastatin, Meropenem
ab 2015 MRGN Ceftolozan Tazobactm, Ceftazidim AvibactamImipenem Cilastatin Relebactam, Meropenem Vaborbactam
ab 2020 Metallo – Betalaktamasen CefiderocolEravacyclin, Plazomicin
? ? …
Krankes Kind & resistente Keime
resistente Keime
Therapie• Claforan hilft nicht …
Harnkultur
Mädchen, 6 Jahre alt
perforierte Appendizitis
„gramnegative Stäbchen in der BK“
DSP – empirische Therapie 2010 - 2017Pat. kommt ins Haus
Trends and correlation between antibacterial consumption and carbapenem resistance in Gram-negative bacteria
DOI: https://doi.org/10.21203/rs.3.rs-61681/v1
Historie der last line
Zeitraum Problem Reserve – Antibiotika
1980 – 2000 Betalaktamasen Amoxicillin Clav, Ampicillin SulbCeftaxim, Ceftriaxon, Ceftazidim
2000 – 2015 ESBL Piperacillin Tazobactam, CefepimImipenem Cilastatin, Meropenem
ab 2015 Meropenem-Resistenz Ceftolozan Tazobactm, Ceftazidim AvibactamImipenem Cilastatin Relebactam, Meropenem Vaborbactam
ab 2020 Metallo – Betalaktamasen CefiderocolEravacyclin, Plazomicin
? ? …
Zufall
Acinetobacter Klebsiella pneumoniae
24.06.2021 Tschechische Republik
Weiblich 15 Jahre altAutobus fliegt 60 m!
Im Detail
Freitag Abend Empirie
Aktuelle Pseudomonas Resistenzen
Antibiotika/Legende sensibel intermediär resistentPiperacillin + Tazobactam 2% 51% 47%Ceftazidim 3% 60% 37%Imipenem 1% 17% 82%Meropenem 0% 0% 100%Ciprofloxacin 3% 72% 26%Amikacin 4% 90% 6%Aztreonam 0% 56% 44%Cefepim 1% 59% 40%Tobramycin 4% 86% 10%Ceftolozan/Tazobactam 93% 0% 7%Ceftazidim/Avibactam 87% 1% 12%
Geschichte• Aufn. Wegen Schulterfraktur
• Harn, BK negativ• CRP 100 bis 200 ondulierend• 3 Wochen Meropenem
• ICU wg. Aspirationspneumonie
Cave +/- intermediät = + bei hoher Dosis
Pseudomonas aeruginosa
Resistent PipTaz
Antibiotika/Legende sensibel intermediär resistent TestungenPiperacillin + Tazobactam 0% 0% 100% 236Ceftazidim 3% 26% 71% 236Imipenem 2% 56% 43% 236Meropenem 52% 5% 43% 236Ciprofloxacin 2% 71% 27% 236Amikacin 4% 91% 5% 236Aztreonam 0% 39% 61% 236Cefepim 1% 39% 60% 235Tobramycin 2% 86% 11% 236Ceftolozan/Tazobactam 94% 0% 6% 233Ceftazidim/Avibactam 84% 1% 15% 233
Resistent Cefepim
Antibiotika/Legende sensibel intermediär resistent TestungenPiperacillin + Tazobactam 2% 20% 78% 179Ceftazidim 4% 24% 72% 180Imipenem 2% 48% 50% 180Meropenem 48% 4% 48% 180Ciprofloxacin 3% 63% 34% 180Amikacin 4% 86% 10% 180Aztreonam 1% 29% 70% 180Cefepim 0% 0% 100% 180Colistin 100% 0% 0% 19Fosfomycin 0% 0% 100% 6Tobramycin 4% 85% 11% 180Ceftolozan/Tazobactam 90% 0% 10% 174Ceftazidim/Avibactam 78% 0% 22% 174Meropenem/Vaborbactam 12% 0% 88% 8
CefiderocolIsolate KDO 2020/2021
Nach den Carbapenemen …
• Ceftolozan-Tazobactam
• Ceftazidim-Avibactam• Meropenem-Vaborbactam• Imipenem-Relebactam
• Cefiderocol
• Neues Pseudomonas-Cephalosporin
• Neuer Betalaktamase-Hemmer
• Neues Wirkprinzip
Meropenem-resistente Gramnegative
Substanzen• Meropenem Vaborbactam- Vaborem ®- 3 x 2+2 gr
• Imipenem + Cilastatin + Relebactam- Recarbrio ®- 4 x 0,5+0,5+0,25
Zulassung• Randomisiert vs. Anderes AB- Harnwegsinfekte- Intraabdominelle Infekte
- Non Inferiorität!- Toxizität!
• resistente Erreger vs. Best available Tx- Colistin, …
- Wirksamkeit- Toxizität- …
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment ofGram-negative nosocomial pneumonia(APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Richard G Wunderink, et al Lan Infect Dis 2021
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment ofGram-negative nosocomial pneumonia(APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Richard G Wunderink, et al Lan Infect Dis 2021
RESTORE-IMI-1: Imipenem/Relebactam for Imipenem-NS GNR
• Imipenem-relebactam was efficacious for imipenem-resistant infections (cUTI, cIAI, HABP/VABP) and showed significantly lower nephrotoxicity (p=0.002).
• Proportion of subjects with a favorable overall response (mMITT population):– Imipenem-Relebactam = 71.4%; Colistin + Imipenen = 70.0%
Results
Additional Key Outcomes Imipenem-Relebactam
Colistin + Imipenem
Favorable Clinical Response at day 28*
71% (15/21) 40% (4/10)
28-d All-cause mortality* 9.5% (2/21) 30% (3/10)
Treatment-emergentnephrotoxicity
10% (3/29) 56% (9/16)
Motsch J et al..O0427. 28th ECCMID, April 2018, Madrid, Spain
*Outcomes in mMITT Population
Cefiderocol for the Treatment of Adult and Pediatric Patients With CysticFibrosis and Achromobacter xylosoxidans InfectionsNathaniel C. Warner et al in CID 2020
Zulassungsstudien
Zulassungstudien
früher jetzt
Historie der last line
Zeitraum Problem Reserve – Antibiotika
1980 – 2000 Betalaktamasen Amoxicillin Clav, Ampicillin SulbCeftaxim, Ceftriaxon, Ceftazidim
2000 – 2015 ESBL Piperacillin Tazobactam, CefepimImipenem Cilastatin, Meropenem
ab 2015 Meropenem-Resistenz Ceftolozan Tazobactm, Ceftazidim AvibactamImipenem Cilastatin Relebactam, Meropenem Vaborbactam
ab 2020 Metallo – Betalaktamasen Cefiderocol(Aztreonam Avibactam, Eravacyclin, Plazomicin)
? ? …
EINGANGS-DATUM
ERREGERkeine EUCAST-Werte für Acinetobacter und Pseudomonas!! Carbapenemase
DD-CZA
DD-MEM DD-C/T DD-IPM ET-ATM ET-MeVa
Komb_ CZA-ATM
BewertungKomb_ CZA-
ATM22.02.2019 Klebsiella pneumoniae -4MRGN OXA-48 22 8 22 7 0,38 12 0,1326.07.2017 Citrobacter freundii-ESBL- 3MRGN ESBL 29 30 25 25 24 0,032 syn.Ef syn.Ef
11.01.2018 Klebsiella pneumoniae -ESBL- 3MRGN C-ase teste negativ 22 24 16 27 256 0,5 0,19 0,19 = S
01.03.2019 Klebsiella pneumoniae -4MRGN Gr B Metallo-Betalaktamasen nichtangewachsen
19.06.2019 Klebsiella pneumoniae -4MRGNOXA 48, Gruppe D Carbapenemasen 6 15 <6 15 24 1 syn.Ef syn.Ef
10.04.2017 Enterobacter cloacae -4MRGNNDM (Gr B Metallo-
Betalaktamasen) 7 7 <6 7 128 16 syn.Ef syn.Ef26.06.2017 Klebsiella pneumoniae -4MRGN NDM 6 7 <6 7 128 12 0,25 0,003= S
06.05.2019 Klebsiella pneumoniae -4MRGNKPC (Gr A Carbapenemasen), SHV und TEM Betalaktamase 18 16 6 12 >256 0,047 0,19 0,127 = S
08.03.2019 Enterobacter cloacae -4MRGN VIM 7 16 <6 14 1 0,38 0,09 0,095 =S26.07.2017 Providentia stuartii - 4 MRGN NDM <6 <6 <6 <6 64 >256 syn.Ef syn.Ef26.07.2017 Klebsiella pneumoniae -ESBL- 3MRGN ESBL 19 26 12 24 >256 0,047 syn.Ef syn.Ef26.07.2017 Serratia marcescens-ESBL-3MRGN ESBL 23 27 16 23 48 0,094 syn.Ef syn.Ef
03.08.2017 Klebsiella pneumoniae -4MRGNOXA-48, ESBL (CTX-M1), SHV
und TEM Betalaktamase 19 8 7 9 >256 16 syn.Ef syn.Ef
11.01.2018 Escherichia coli - 4MRGNESBL (CTX-M1)
und OXA-1 Betalaktamase 16 14 7 21 >256 3
leichter komb.Ef
fektleichter
komb.Effekt
29.07.2019 Klebsiella pneumoniae -4MRGN AmpC 10 0 0 13 >256 0,75 32 0,25 = S09.08.2019 Acinetobacter baumannii- 4 MRGN OXA-23, OXA-51 0 0 11 7 32 256 12 1,125= I02.08.2019 Enterobacter cloacae -4MRGN VIM 0 0 0 0 12 >256 0,5 0,04=S18.07.2019 Enterobacter cloacae -4MRGN VIM 0 0 0 0 24 256 1 0,05 = S19.08.2019 Pseudomonas aeruginosa- 4 MRGN - 0 0 17 0 64 256 8 1,125 = I19.08.2019 Pseudomonas aeruginosa- 4 MRGN - 0 0 19 0 64 256 8 0,795 = I12.08.2019 Enterobacter cloacae -4MRGN VIM 0 0 0 0 1 256 0,19 0,19=S08.08.2019 Klebsiella pneumoniae -4MRGN OXA-48 12 0 0 0 >256 256 0,25 0,25 =S21.08.2019 Enterobacter cloacae -4MRGN VIM 0 0 0 0 1,5 256 0,5 0,3 = S26.09.2019 Klebsiella pneumoniae -ESBL- 3MRGN 25 29 0,5 28 32 0,047 0,03 0,17 =S26.09.2019 Pseudomonas aeruginosa- 4 MRGN NDM <6 <6 <6 <6 256 256 32 0,25 = S26.09.2019 Providentia stuartii AmpC, (NDM?) <6 <6 <6 <6 12 16 0,13 0,001 =S26.09.2019 Proteus mirabilis- ESBL- 4 MRGN <6 16 <6 20 256 1,5 0,5 0,004 =S26.09.2019 Klebsiella pneumoniae -4MRGN KPC <6 10 <6 16 256 8 1 0,008 = S31.12.2019 Enterobacter cloacae -4MRGN NDM <6 >32 <6 - 4 3 0,02 S02.01.2020 Enterobacter cloacae -4MRGN NDM 8 4 0,02 S17.01.2020 Pseudomonas aeruginosa- 4 MRGN ? 64 24 8 0,792 = I
Aztreonam & Avibactam
Frau – 60 Jahrekomplizierte Pneumonie mit Empyembildung li. myotone Dystrophie Typ 1, Morbus Curschmann-Steinert
Fetcroja - Stenotrophomonas
Stenotrophomonas maltophiliaKDO 2021
< < CLSI > >
Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic
Historie der last line
Zeitraum Problem Reserve – Antibiotika
1980 – 2000 Betalaktamasen Amoxicillin Clav, Ampicillin SulbCeftaxim, Ceftriaxon, Ceftazidim
2000 – 2015 ESBL Piperacillin Tazobactam, CefepimImipenem Cilastatin, Meropenem
ab 2015 MRGN Ceftolozan Tazobactm, Ceftazidim AvibactamImipenem Cilastatin Relebactam, Meropenem Vaborbactam
ab 2020 Metallo – Betalaktamasen CefiderocolEravacyclin, Plazomicin
? ? …
The end …
Das „letzte“ Antibiotikum wird es nicht geben
William Huffman Stewart Niccolò Machiavelli
Die Zeit ist die Mutter der „Wahrheit“… it is time to close the book …
Recommended